U.S. Department of Justice Drug Enforcement Administration ...
U.S. Food and Drug Administration
description
Transcript of U.S. Food and Drug Administration
![Page 1: U.S. Food and Drug Administration](https://reader035.fdocuments.net/reader035/viewer/2022062520/56815c8c550346895dca9e6f/html5/thumbnails/1.jpg)
U.S. Food and Drug Administration
Notice: Archived DocumentThe content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may be outdated.
![Page 2: U.S. Food and Drug Administration](https://reader035.fdocuments.net/reader035/viewer/2022062520/56815c8c550346895dca9e6f/html5/thumbnails/2.jpg)
Regulatory Background
Grant Williams, M.D.Deputy Director, DODP
![Page 3: U.S. Food and Drug Administration](https://reader035.fdocuments.net/reader035/viewer/2022062520/56815c8c550346895dca9e6f/html5/thumbnails/3.jpg)
Acknowledgements
• Planning: NCI, AACR, ASCO• ASCO
– Logistics and panelist support– Mary Wilson, Deborah Kamin
• FDA– Dianne Spillman
![Page 4: U.S. Food and Drug Administration](https://reader035.fdocuments.net/reader035/viewer/2022062520/56815c8c550346895dca9e6f/html5/thumbnails/4.jpg)
Workshop outline• Background presentations
– Regulations and past endpoints– Time to Progression (TTP)– Surrogates and non-inferiority
• Question-based discussions– First-line treatment setting– Second and subsequent therapy– Other endpoints– Adjuvant treatment setting– Rectal cancer and neoadjuvant therapy
![Page 5: U.S. Food and Drug Administration](https://reader035.fdocuments.net/reader035/viewer/2022062520/56815c8c550346895dca9e6f/html5/thumbnails/5.jpg)
Outline of Presentation
• FDA requirements for new drug approval
• Regular approval of cancer drugs: end points used
• Accelerated approval of cancer drugs
![Page 6: U.S. Food and Drug Administration](https://reader035.fdocuments.net/reader035/viewer/2022062520/56815c8c550346895dca9e6f/html5/thumbnails/6.jpg)
Requirements for Drug Approval
• Safety (FDAC, 1933)• Efficacy demonstrated in adequate and well
controlled studies (1962)• Basis for efficacy:
– Regular approval• Clinical benefit, or• Established surrogate for clinical benefit
– Accelerated approval• Surrogate (reasonably likely to predict CB)
![Page 7: U.S. Food and Drug Administration](https://reader035.fdocuments.net/reader035/viewer/2022062520/56815c8c550346895dca9e6f/html5/thumbnails/7.jpg)
How many trials?• Usually more than one trial is needed.
Substantial evidence: “Adequate and well-controlled investigations”
• Sometimes a single trial may suffice.– FDAMA (1997) single trial plus other supportive evidence– 1998 FDA Effectiveness Guidance:
• Multicenter trial• Statistically strong evidence• Important clinical benefit• Additional trials not ethical
![Page 8: U.S. Food and Drug Administration](https://reader035.fdocuments.net/reader035/viewer/2022062520/56815c8c550346895dca9e6f/html5/thumbnails/8.jpg)
Oncology Efficacy Supplements
Only one additional trial may be needed for closely related indications1:– Advanced cancer and earlier cancer– Different dosing regimens– New combinations of drugs
1http://www.fda.gov/cder/guidance/1397fnl.pdf
![Page 9: U.S. Food and Drug Administration](https://reader035.fdocuments.net/reader035/viewer/2022062520/56815c8c550346895dca9e6f/html5/thumbnails/9.jpg)
Regular Approval Endpoints in Oncology
![Page 10: U.S. Food and Drug Administration](https://reader035.fdocuments.net/reader035/viewer/2022062520/56815c8c550346895dca9e6f/html5/thumbnails/10.jpg)
Clinical Benefit Endpoints Supporting Regular Drug Approval
• Survival • Improvement in tumor-related
symptoms
![Page 11: U.S. Food and Drug Administration](https://reader035.fdocuments.net/reader035/viewer/2022062520/56815c8c550346895dca9e6f/html5/thumbnails/11.jpg)
Established Surrogates Supporting Regular Approval
• Disease-free survival (selected settings)• Complete response rates in some
settings (e.g., acute leukemia)• Partial response rate in some settings
(e.g., hormonal treatment of breast cancer)
![Page 12: U.S. Food and Drug Administration](https://reader035.fdocuments.net/reader035/viewer/2022062520/56815c8c550346895dca9e6f/html5/thumbnails/12.jpg)
DODP: Endpoints for Approval (1/1/90 - 11/1/02)
Approvals not based on Survival: – 73% (48/66) of all approvals– 67% (37/55) excluding accelerated
approvals
![Page 13: U.S. Food and Drug Administration](https://reader035.fdocuments.net/reader035/viewer/2022062520/56815c8c550346895dca9e6f/html5/thumbnails/13.jpg)
Summary of Endpoints for DODP RegularApprovals (1/1/90 - 11/1/02) *
Total 55Survival 18RR 26 -RRalone -10 -RR+ Tumor Specific Symptoms -9 -RR+ TTP -7 Tumor Specific Symptoms 4DFS 2TTP 1Recurrence Malignant PleuralEffusion
2
Occurrence Breast Cancer 2* Derived from Johnson et al., JCO 21: 1404, 2003
![Page 14: U.S. Food and Drug Administration](https://reader035.fdocuments.net/reader035/viewer/2022062520/56815c8c550346895dca9e6f/html5/thumbnails/14.jpg)
Tumor-related symptoms
• Mitoxantrone -Pain• Bisphosphonates-Skeletal morbidity scale• Daunozome -Visible lesions of KS• Photofrin -Dysphagia scale
![Page 15: U.S. Food and Drug Administration](https://reader035.fdocuments.net/reader035/viewer/2022062520/56815c8c550346895dca9e6f/html5/thumbnails/15.jpg)
Accelerated approval • Serious or life-threatening disease• Drug must provide benefit over available
therapy• Surrogate endpoint may be used• Surrogate endpoint must be reasonably likely
to predict clinical benefit• Post marketing studies must verify clinical
benefit
![Page 16: U.S. Food and Drug Administration](https://reader035.fdocuments.net/reader035/viewer/2022062520/56815c8c550346895dca9e6f/html5/thumbnails/16.jpg)
Evidence for Accelerated Approval
• Substantial evidence from well controlled clinical trials regarding a surrogate endpoint
• NOT: Borderline evidence regarding a clinical benefit endpoint
![Page 17: U.S. Food and Drug Administration](https://reader035.fdocuments.net/reader035/viewer/2022062520/56815c8c550346895dca9e6f/html5/thumbnails/17.jpg)
Single Arm Trials (SAT) and Accelerated approval (AA)
• SAT require few patients• SAT for AA limit study to refractory
disease• SAT have limited ability to evaluate
valuable endpoints such as TTP, QOL, and Survival
![Page 18: U.S. Food and Drug Administration](https://reader035.fdocuments.net/reader035/viewer/2022062520/56815c8c550346895dca9e6f/html5/thumbnails/18.jpg)
Randomized Trials (RT) and Accelerated approval (AA)
• Allows AA at any disease stage (surrogate beats available therapy)
• Allows “add-on” design (A vs A + B)
• Allows a variety of endpoints
• Defines individual drug contribution– (oxaliplatin vs 5FU/LCV versus oxaliplatin + 5FU/LCV)
![Page 19: U.S. Food and Drug Administration](https://reader035.fdocuments.net/reader035/viewer/2022062520/56815c8c550346895dca9e6f/html5/thumbnails/19.jpg)
ODAC Meeting on: Accelerated Approvals
(March 2003)
• 19 NDAs or BLAs for new treatment indications (involving 16 drugs)
• Confirmatory studies should be part of drug development plan
• Consider interim analysis of surrogate endpoint for AA
![Page 20: U.S. Food and Drug Administration](https://reader035.fdocuments.net/reader035/viewer/2022062520/56815c8c550346895dca9e6f/html5/thumbnails/20.jpg)
Summary of Presentation• FDA requirements
– Evidence from Trials or Trial+– RA: Clinical Benefit or accepted surrogate– AA: Advantage over available therapy with regard
to a “reasonably likely surrogate”• Cancer Approvals• Important question:
– Should TTP be considered an accepted surrogate in any colon cancer setting?